Siha細胞

細胞名稱： 人子宮頸鱗癌細胞  Siha細胞

細胞別稱：Siha; SIHA

貨號：TCH-C326

規(guī)格： 1X10^6

價格：1400元 (干冰運輸需另加200元干冰費)

種屬來源：人

組織來源：宮頸

特征：宮頸鱗癌

細胞形態(tài)：上皮細胞樣

生長特性：貼壁生長

培養(yǎng)體系：DMEM-H+10%FBS+1%P/S

配套培養(yǎng)基貨號：TCH-G326

傳代比例：1:3-1:6，每2-3天換液一次

Siha細胞傳代周期：48-72 h

培養(yǎng)條件：氣相：95%空氣+5%CO2，溫度：37℃

凍存條件：60%基礎(chǔ)培養(yǎng)基+30%FBS+10%DMSO，液氮儲存

質(zhì)量檢測：細菌、真菌、支原體檢測均為陰性

  Siha細胞來源于一位日本的手術(shù)切除的腫瘤組織。電鏡下可以看到細胞間典型的橋粒和細胞質(zhì)中大量的張力絲。1975年發(fā)現(xiàn)有支原體污染，而后被去除。該細胞整合有HPV16基因組，每個細胞中有1~2個拷貝。

    蘇州阿爾法生物除了提供細胞系購買，細胞株購買，肺癌細胞株，ht-29細胞 ，血管內(nèi)皮細胞株，肝癌細胞株，腫瘤細胞株，胃癌細胞株，hela細胞株，Siha細胞，s180細胞株，hela細胞株，CHO細胞株，間充質(zhì)干細胞，還提供MEM培養(yǎng)基,DMEM,F12培養(yǎng)基,RPMI培養(yǎng)基等基礎(chǔ)培養(yǎng)基，干細胞培養(yǎng)基,培養(yǎng)基添加劑,間充質(zhì)干細胞培養(yǎng)基 ,完全培養(yǎng)基,低血清培養(yǎng)基,胎牛血清,雞血清等細胞培養(yǎng)試劑以及實驗耗材，實驗室儀器等。

參考文獻：

"Annunziata C, et al. Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma. Int J Cancer 143(5): 1153-1161, 2018. PubMed: 29603728

Baker CC, et al. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 61: 962-971, 1987. PubMed: 3029430

Pater MM, Pater A. Human papillomavirus types 16 and 18 sequences in carcinoma cell lines of the cervix. Virology 145: 313-318, 1985. PubMed: 2992153

Yee C, et al. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119: 361-366, 1985. PubMed: 2990217

Friedl F, et al. Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc. Soc. Exp. Biol. Med. 135: 543-545, 1970. PubMed: 5529598

Scheffner M, et al. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA 88: 5523-5527, 1991. PubMed: 1648218

Hendricks DT, et al. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res. 57: 2112-2115, 1997. PubMed: 9187105

Olive PL, Banath JP. Multicell spheroid response to drugs predicted with the comet assay. Cancer Res. 57: 5528-5533, 1997. PubMed: 9407963"